Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: The invention provides a protein comprising hepatitis B core antigen (HBcAg) with a sugar attached to an e1 loop. The protein may comprise a first and a second copy of HBcAg in tandem, wherein one or both copies of HBcAg has a sugar attached to the e1 loop. The first copy may have a sugar attached to the e1 loop and the second copy may comprise a peptide epitope in the e1 loop. The protein may be used to induce an immune response against the sugar and hence act as a vaccine.

Abstract: The invention provides a protein comprising hepatitis B core antigen (HBcAg) with a sequence of the formula XpZqXr in an e1 loop, wherein X is a negatively charged amino acid residue, Z is a positively charged amino acid residue, and p, q N and r are each independently an integer from 1 to 12, and wherein a sugar is attached to a Z residue. The protein may comprise a first and a second copy of HBcAg in tandem, wherein one or both copies of HBcAg has a sugar attached to the e1 loop. The first copy may have a sugar attached to the e1 loop and the second copy may comprise a peptide epitope in the e1 loop. The protein may be used to induce an immune response against the sugar and hence act as a vaccine.

Abstract: The invention provides a protein comprising hepatitis B core antigen (HBcAg) with a sugar attached to an e1 loop. The protein may comprise a first and a second copy of HBcAg in tandem, wherein one or both copies of HBcAg has a sugar attached to the e1 loop. The first copy may have a sugar attached to the e1 loop and the second copy may comprise a peptide epitope in the e1 loop. The protein may be used to induce an immune response against the sugar and hence act as a vaccine.

Abstract: The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises a single-domain antibody fragment in the el loop.

Abstract: An electrical connector assembly includes a first electrical connector and a second electrical connector. The first electrical connector includes a recess formed in an outer shell of the first electrical connector. The second electrical connector includes an integrated elongated spring clip extending from the second electrical connector. The recess is shaped to receive a portion of the elongated spring clip, which interlocks the first and second electrical connectors when positioned in the recess.

Abstract: An electrical connector assembly includes a first electrical connector and a second electrical connector. The first electrical connector includes a door for protecting contacts of the first electrical connector from environmental conditions when the first electrical connector is in an unmated condition. The second electrical connector includes an integral elongated strap and an integral clasp positioned approximate an outer shell of the second electrical connector. The strap is shaped to contact the door of the first electrical connector and interlock with the clasp to interlock the first and second electrical connectors when the first and second electrical connectors are mated.

Abstract: An electrical connector assembly includes a first electrical connector and a second electrical connector. The first electrical connector includes a door for protecting contacts of the first electrical connector from environmental conditions when the first electrical connector is in an unmated condition. The second electrical connector includes an integral elongated strap and an integral clasp positioned approximate an outer shell of the second electrical connector. The strap is shaped to contact the door of the first electrical connector and interlock with the clasp to interlock the first and second electrical connectors when the first and second electrical connectors are mated.

Abstract: A breakaway switch assembly for detecting the unintended separation of a pair of connected vehicles or the like, of the type having a housing enclosure which slidably receives a pin-type actuator that operates an internal switch when pulled from the housing upon separation of the connected vehicles etc., incorporates a fully assembled, self-contained switch unit of a commercially known type, rather than a special switch assembly having long, resilient contact-carrying spring arms that must be carefully and tediously mounted in specially designed housings, as was the most prevalent practice heretofore. The self-contained switch unit so utilized preferably has an enclosing outer housing or body which protects the interior switch mechanism, contacts, etc., from the elements and also provides protruding flanges or the like which facilitate easy and fast mounting of the entire unit within the housing.

Abstract: A DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of foot and mouth disease virus RNA and in particular coding for at least one protein of foot and mouth disease virus. The DNA molecule can be inserted into a DNA cloning vehicle capable of expressing the DNA molecule, after a suitable host cell has been transformed by the cloning vehicle. The expression product can be incorporated into a vaccine for stimulating antibodies against FMDV. Methods for producing the DNA molecule, recombinant cloning vehicle and transformed host cell are described.